December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by NEOK Bio, Inc.

News headline image
NEOK Bio Initiates Phase 1 Clinical Trials of Both Lead Bispecific ADCs
From NEOK Bio, Inc.
Via Business Wire
News headline image
NEOK Bio Presentations at AACR 2026 Annual Meeting Showcase Potential of a Differentiated Bispecific Antibody Drug Conjugate Pipeline
From NEOK Bio, Inc.
Via Business Wire
News headline image
NEOK Bio Secures FDA IND Clearance for NEOK002, a Novel EGFR/MUC1 Bispecific ADC for Treatment of Solid Tumors
From NEOK Bio, Inc.
Via Business Wire
News headline image
NEOK Bio Receives FDA IND Approval for NEOK001, A First-In-Class B7-H3/ROR1 Bispecific ADC for Treatment of Solid Tumor Cancers
From NEOK Bio, Inc.
Via Business Wire
News headline image
NEOK Bio Launches from Stealth with $75 Million Series A to Advance Next-Generation Bispecific Antibody Drug Conjugates (ADC) in Oncology
From NEOK Bio, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.